肿瘤防治研究2023年第50卷第1期CancerResPrevTreat,2023,Vol.50,No.1·69·doi:10.3971/j.issn.1000-8578.2023.22.0593胸腔镜肺叶切除术中肺动、静脉切断顺序对非小细胞肺癌患者手术疗效与安全性影响的系统评价白向豆1，洪子强1，崔百强1，杨宁1，贺晓阳1，金大成2，苟云久1,2EffectofSequenceofPulmonaryArteryandVeinTransectioninThoracoscopicLobectomyonEfficacyandSafetyofPatientswithNon-smallCellLungCancer:ASystematicEvaluationBAIXiangdou1,HONGZiqiang1,CUIBaiqiang1,YANGNing1,HEXiaoyang1,JINDacheng2,GOUYunjiu1,21.TheFirstClinicalMedicalCollegeofGansuUniversityofChineseMedicine,Lanzhou730000,China;2.DepartmentofThoracicSurgery,GansuProvincialHospital,Lanzhou730000,ChinaCorrespondingAuthor:GOUYunjiu,E-mail:gouyunjiu@163.comAbstract:ObjectiveTosystematicallyevaluatetheeffectofsequenceofpulmonaryarteryandveintransectioninthoracoscopiclobectomyontheefficacyandsafetyofpatientswithnon-smallcelllungcancer.MethodsPubMed,EMbase,WebofScience,TheCochraneLibrary,CNKI,Wanfang,VIPandCBMdatabasesweresearchedfortheresearchesonThepost-operativeefficacyofpulmonaryarteriovenousandpulmonaryveinresectionsequenceinthoracoscopiclobectomyfornon-smallcelllungcancer.TheretrievaltimeisfromthedatabaseconstructiontoMay2022.Meta-analysiswasperformedusingRevMan5.4software.ResultsEightarticleswereincluded,including3randomizedcontrolledstudiesand5cohortstudies,withatotalof1810patients.Meta-analysisresultsshowedthat:Theoperativetime(MD=13.34,95%CI(7.36,19.32),P<0.0001)andintraoperativebloodloss(MD=45.29,95%CI(40.24,50.35),P<0.0001)inthegroupwithprioritypulmonaryveinresectionweresignificantlyhigherthanthoseinthegroupwithprioritypulmonaryveinresection.Thedifferencewasstatisticallysignificant.However,thebenefitsofOS(HR=1.34,95%CI(1.12,1.60),P=0.001)andDFS(HR=1.44,95%CI(1.18,1.76),P=0.0003)inthegroupofprioritypulmonaryveintransectionweresignificantlybetterthanthoseinthegroupofprioritypulmonaryarterytransection,withstatisticallysignificantdifferences.ConclusionPrioritypulmonaryveintransectionduringthoracoscopiclobectomyeffec...
